Literature DB >> 11959599

Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

David H Wright1, Brent W Gunderson, Laurie B Hovde, Gigi H Ross, Khalid H Ibrahim, John C Rotschafer.   

Abstract

Six strains of staphylococci were exposed to levofloxacin, moxifloxacin, or trovafloxacin in an in vitro pharmacodynamic model under both aerobic and anaerobic conditions. Each agent demonstrated a rapid 3-log(10) kill versus susceptible isolates regardless of condition. Against clinical isolates with reduced susceptibility, regrowth occurred by 24 h and was frequently associated with further increases in MICs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959599      PMCID: PMC127187          DOI: 10.1128/AAC.46.5.1561-1563.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J Li; J Turnidge; R Milne; R L Nation; K Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 3.  Fluoroquinolones.

Authors:  J A O'Donnell; S P Gelone
Journal:  Infect Dis Clin North Am       Date:  2000-06       Impact factor: 5.982

4.  Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography.

Authors:  D H Wright; V K Herman; F N Konstantinides; J C Rotschafer
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-05-08

5.  Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.

Authors:  M A Cooper; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1991-09       Impact factor: 5.790

Review 6.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

7.  Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads.

Authors:  R A Zabinski; A J Larsson; K J Walker; S S Gilliland; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

Authors:  R A Zabinski; K J Walker; A J Larsson; J A Moody; G W Kaatz; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.

Authors:  R A Zabinski; K Vance-Bryan; A J Krinke; K J Walker; J A Moody; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  The importance of oxygen in the killing of bacteria by ofloxacin and ciprofloxacin.

Authors:  I Morrissey; J T Smith
Journal:  Microbios       Date:  1994
  10 in total
  6 in total

1.  Resolution of ofloxacin-ciprofloxacin and ofloxacin-norfloxacin binary mixtures by flow-injection chemiluminescence in combination with partial least squares multivariate calibration.

Authors:  J A Murillo; A Alañón Molina; A Muñoz de la Peña; I Durán Merás; A Jiménez Girón
Journal:  J Fluoresc       Date:  2007-06-19       Impact factor: 2.217

2.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 4.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.

Authors:  Joseph J Dajcs; Brett A Thibodeaux; Mary E Marquart; Dalia O Girgis; Mullika Traidej; Richard J O'Callaghan
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

6.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.